Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RPS6KA1
REST API REST API
Homo sapiens
RPS6KA1 is differentially expressed in 251 experiments: 131 organism parts: bone marrow, spleen, ... (129 more);, 212 disease states: normal, acute myeloid leukemia, ... (210 more);, 90 cell types 388 cell lines 29 compound treatments and 62 other conditions.
Synonyms RSK, RSK1, HU-1
Orthologs Rps6ka1 (Rattus norvegicus)   KS6AA_CHICK (Gallus gallus)   rps6ka1 (Danio rerio)   A4IFF4_BOVIN (Bos taurus)   ENSCING00000005582 (Ciona intestinalis)   Rps6ka1 (Mus musculus)   rps6ka1 (Xenopus laevis)   RPS6KA1 (Canis familiaris)   S6kII (Drosophila melanogaster)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, cytosol, phosphotransferase activity, alcohol group as acceptor, caspase inhibitor activity, innate immune response, membrane, protein tyrosine kinase activity, stress-activated MAPK cascade, ATP binding, magnesium ion binding, axon guidance, synaptic transmission, transferase activity, transferring phosphorus-containing groups, spindle, nucleotide binding, protein serine/threonine kinase activity, nucleoplasm, signal transduction, lipopolysaccharide biosynthetic process, negative regulation of caspase activity, protein kinase activity, intracellular protein kinase cascade, toll-like receptor 4 signaling pathway, toll-like receptor signaling pathway, toll-like receptor 3 signaling pathway, nerve growth factor receptor signaling pathway, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, protein phosphorylation, MyD88-independent toll-like receptor signaling pathway, toll-like receptor 1 signaling pathway
InterPro Term Pkinase_C, AGC-kinase_C, Prot_kinase_cat_dom, Ribosomal_S6_kinase_II, LipoPS_kinase, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q15418, Q5SVM7, Q5SVM6, B7Z2K7, E9PMM7, E9PPN6, E9PPC1, E9PRI4, E9PAN7, E9PGT4, E9PGT3, A6NND1
Search EB-eye ENSG00000117676
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-19397, E-GEOD-2450, ... (33 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
K562
2
E-GEOD-24147, E-GEOD-96
HH
1
E-MTAB-37
J82
1
E-MTAB-37
GM09581
1
E-TABM-321
GM10847
1
E-GEOD-19466
382 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-19397, E-GEOD-3920, E-GEOD-13909, E-GEOD-20677, ... (45 experiments)

Factor Value U/D Experiments
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
testis - leydig cell
2
E-AFMX-5, E-TABM-145
epidermoid
1
E-GEOD-19397
chondrocyte
1
E-TABM-130
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-22529, E-GEOD-15960, ... (48 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-MTAB-37, E-MTAB-62, E-GEOD-4412, E-GEOD-4290
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
lymphoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
206 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-GEOD-6462, ... (20 experiments)

Factor Value U/D Experiments
none
4
6
E-GEOD-2803, E-GEOD-5824, E-GEOD-412, E-GEOD-20719, E-MEXP-1269, ... (10 experiments)
endotoxin
1
E-GEOD-3026
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
granulocyte-colony stimulating factor
1
E-GEOD-7400
vanadium pentoxide
1
E-GEOD-5339
Cxcl12
1
E-GEOD-7307
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-2034, E-GEOD-1563, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-3013

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-TABM-321, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-MEXP-2657, E-MEXP-1446, E-GEOD-22278, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (26 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-36, E-GEOD-1926

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Processing time: 0.466 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM